AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $5.10 million which missed the analyst consensus estimate of $7.58 million by 32.71 percent. This is a 44.44 percent decrease over sales of $9.18 million the same period last year.